Search Within

Michael William Lattanzi

Formats
  1. Meeting Abstract (5)
  2. Correspondence (1)
  3. Journal Article (1)
  4. Review (1)
Groups
  1. Department of Medicine (8)
  2. GME, Medicine (8)
  3. Genitourinary Oncology Service (8)
  4. Graduate Medical Education (8)
  5. Hematology-Oncology Fellows (8)
  6. Solid Tumor Oncology Division (8)

More Groups

People
  1. Jonathan Rosenberg (7)
  2. Gopakumar Iyer (6)
  3. Min Yuen Teo (6)
  4. Samuel Funt (6)
  5. David Aggen (5)
  6. Dean Bajorin (5)

More People

Years
  1. 2022 (5)
  2. 2021 (2)
  3. 2020 (1)
Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer Research (1)
  3. Expert Review of Anticancer Therapy (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (1)
  3. Taylor & Francis Group (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer
    Meeting Abstract

    Guercio, B. J.; Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Chen, Z.; Lattanzi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Reply to S. Zhang
    Correspondence

    Lattanzi, M.; Funt, S. A.; Rosenberg, J. E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts)
    Meeting Abstract

    Lattanzi, M.; Niederhausern, A.; Zheng, J.; Bahadur, N.; Nichols, C.; Barton, L.; Gandhi, F.; Chan, K.; Insinga, A.; Philip, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial
    Meeting Abstract

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H. A.; Quinlan, C.; Teo, M. Y.; Kamradt, J.; Khalil, M. F.; Ostrovnaya, I.; McCoy, A. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience
    Meeting Abstract

    Guercio, B. J.; Gandhi, J.; Teo, M. Y.; Lattanzi, M.; Funt, S. A.; Aggen, D. H.; Chen, Y. B.; Fine, S.; Pietzak, E. J.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The emerging role of antibody-drug conjugates in urothelial carcinoma
    Review

    Lattanzi, M.; Rosenberg, J. E.
    Expert Review of Anticancer Therapy (2020)

    Fulltext@MSK | Save